Donald J. McCaffrey

As President and Chief Executive Officer of Zenith, Mr. McCaffrey has 40+ years of corporate management experience including over 20 years in drug discovery and development. Don’s expertise in corporate operations has attracted an international team of experts, including world-renowned oncology Key Opinion Leaders. He has facilitated many high-profile collaborations and partnerships with leading organizations including Pfizer, Newsoara BioPharm Co., Ltd. (Newsoara), National Cancer Institute (NCI), University of California San Francisco (UCSF), and Merck.

In addition to Zenith, Don serves as President and CEO of Resverlogix Corp. (TSX: RVX), (“Resverlogix”), a late-stage clinical biotechnology company. Resverlogix has the most advanced epigenetic drug, apabetalone, which received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) in 2020, the first for a major cardiovascular indication. Zenith was spun out of Resverlogix in 2013.